Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding AG (RHHBY) is a global pioneer in biotechnology and diagnostics, driving innovations in personalized healthcare through groundbreaking pharmaceuticals and advanced diagnostic solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, research breakthroughs, and strategic initiatives shaping modern medicine.
Access authoritative information on Roche's financial performance, regulatory milestones, and therapeutic advancements. Our curated news collection includes:
• Earnings reports and investor communications
• FDA/EMA regulatory updates
• Clinical trial results and R&D partnerships
• Diagnostic technology launches
• Strategic acquisitions and collaborations
Bookmark this page for comprehensive tracking of Roche's progress in oncology, immunology, and molecular diagnostics. Stay informed about developments impacting one of healthcare's most influential innovators through verified updates from primary sources.
Rhea-AI Summary
Roche (OTCQX: RHHBY) announced key leadership changes in its enlarged Corporate Executive Committee. Dr. Hans Clevers, Head of Roche Pharma Research and Early Development (pRED), will retire at the end of August 2025. Dr. Clevers, who joined the Board in 2019 and became pRED Head in March 2022, will continue leading the Institute of Human Biology until a successor is named.
Additionally, Barbara Schädler, Head of Group Communications, will retire from the company at the end of 2025. Schädler, who joined Roche in 2019, was credited with modernizing the company's communication function and leading the internal COVID-19 taskforce. The company will announce successors for both positions in due course.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
-
Rhea-AI Summary
Roche announced promising phase I/II data for NXT007, a next-generation bispecific antibody for hemophilia A treatment. The NXTAGE study showed NXT007 achieved zero treated bleeds in highest dose groups and demonstrated a tolerable safety profile with no thromboembolic events. The study included 30 participants aged 12-65 across four cohorts receiving subcutaneous NXT007 every 2-4 weeks. Three phase III studies are planned for 2026, including a head-to-head comparison with Roche's Hemlibra. NXT007 aims to provide haemostatic normalization and reduced treatment burden for patients. The drug leverages Roche's expertise in hemophilia A and bispecific antibody development, with additional phase II data expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Summary
Roche announced significant results from the phase III SUNMO study for its Lunsumio and Polivy combination therapy in treating relapsed/refractory large B-cell lymphoma. The combination showed remarkable efficacy with 11.5 months median progression-free survival, three times longer than the comparison treatment R-GemOx. The therapy demonstrated a 59% reduction in disease progression risk and doubled the complete response rate at 51.4% versus 24.3% for R-GemOx. The treatment showed a favorable safety profile suitable for outpatient use, with low incidence of cytokine release syndrome. This novel combination of a bispecific antibody and antibody-drug conjugate avoids traditional chemotherapy and has been added to NCCN Guidelines as a category 2A recommendation for second-line DLBCL treatment in non-transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
Rhea-AI Summary
Genentech's Phase III SUNMO study demonstrated significant success in treating relapsed/refractory large B-cell lymphoma using a combination of Lunsumio and Polivy. The treatment showed a median progression-free survival of 11.5 months, three times longer than the standard R-GemOx therapy, and reduced disease progression risk by 59%. The combination therapy achieved a 70.3% objective response rate and doubled complete response rate to 51.4% compared to R-GemOx. Notably, 72.6% of complete responders maintained remission after one year. The treatment showed a favorable safety profile suitable for outpatient use, with low incidence of cytokine release syndrome and no neurotoxicity syndrome events reported. This chemotherapy-free combination represents a potential breakthrough as the first bispecific antibody and antibody-drug conjugate treatment for LBCL, with results to be submitted to global health authorities including the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
-
Rhea-AI Summary
Genentech and AbbVie announced that their Phase III VERONA study investigating Venclexta (venetoclax) plus azacitidine for previously untreated higher-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint of overall survival. The global study involved approximately 500 patients across 220 sites, comparing Venclexta plus azacitidine to placebo plus azacitidine. While the safety profile aligned with known risks and showed no unexpected signals, the trial's failure represents a setback in the treatment development for higher-risk MDS patients. The companies plan to present complete data at an upcoming medical meeting in 2025, and the results do not affect Venclexta's currently approved indications or ongoing studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
News
Rhea-AI Summary
Genentech, a Roche Group company, has announced plans to advance prasinezumab, a first-in-class anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. The decision follows encouraging results from the Phase IIb PADOVA study and open-label extensions of both PADOVA and PASADENA trials. While the drug missed statistical significance in its primary endpoint of confirmed motor progression, it demonstrated potential clinical benefits when combined with symptomatic treatments. The studies provided the first biomarker evidence of prasinezumab affecting underlying disease biology, with positive trends in reduced motor progression at 104 weeks that appeared sustained over longer periods. Currently, over 750 people with early-stage Parkinson's are participating in ongoing long-term safety and efficacy studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
Rhea-AI Summary
Roche announced plans to advance prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. The decision follows encouraging results from the Phase IIb PADOVA study and open-label extensions of PADOVA and PASADENA studies. While the primary endpoint of time to confirmed motor progression missed statistical significance, the drug showed positive trends in reducing motor progression at 104 weeks, with effects appearing sustained over longer periods. The studies provided first biomarker evidence of prasinezumab impacting underlying disease biology. The development aims to address the needs of over 10 million Parkinson's disease patients globally, with prasinezumab potentially becoming the first disease-modifying treatment for the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
Rhea-AI Summary
Roche has announced immediate dosing restrictions for Elevidys gene therapy in non-ambulatory Duchenne muscular dystrophy (DMD) patients following two fatal cases of acute liver failure. The company has halted commercial treatment and paused clinical trials for non-ambulatory patients, while treatment continues for ambulatory patients where benefit-risk remains positive. The fatal cases occurred among approximately 140 non-ambulatory patients treated globally. Multiple clinical trials, including ENVISION, ENVOL, and others, are affected by these restrictions. Elevidys is currently approved in eight territories outside the U.S., with Roche and Sarepta Therapeutics collaborating on commercialization and clinical studies. DMD affects 1 in 5,000 boys worldwide, causing progressive muscle weakness and eventual loss of mobility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Roche (RHHBY) has received European Commission approval for a new tablet formulation of Evrysdi (risdiplam), marking a significant advancement in Spinal Muscular Atrophy (SMA) treatment. The 5mg tablet, which can be swallowed whole or dispersed in water, offers room-temperature stability and doesn't require refrigeration. This new formulation maintains the same efficacy and safety as the original oral solution, as demonstrated in bioequivalence studies. Evrysdi, the only non-invasive disease-modifying SMA treatment, has treated over 18,000 patients globally. The tablet is approved for patients aged two years or older, weighing 20kg or more, who can swallow without a feeding tube. The original oral solution will remain available for patients requiring different doses or preferring that format.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
Rhea-AI Summary
Roche announced positive Phase III IMforte study results for Tecentriq combined with lurbinectedin as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The combination showed remarkable efficacy, reducing disease progression/death risk by 46% and death risk by 27% compared to Tecentriq alone. The median overall survival improved to 13.2 months versus 10.6 months with Tecentriq monotherapy, while progression-free survival increased to 5.4 months versus 2.1 months. The study marks the first Phase III trial in ES-SCLC first-line maintenance demonstrating significant improvements in both progression-free and overall survival. The treatment showed consistent safety profiles with no new safety signals, offering hope for ES-SCLC patients, where only 20% survive beyond two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
FAQ
What is the current stock price of Roche Hldg (RHHBY)?
The current stock price of Roche Hldg (RHHBY) is $40.2 as of July 16, 2025.
What is the market cap of Roche Hldg (RHHBY)?
The market cap of Roche Hldg (RHHBY) is approximately 279.1B.
Roche Hldg